Cambridge Healthtech Institute’s 3^rd Annual

Bispecific Case Studies & Clinical Relevance

Lessons Learned and Mitigation Strategies

August 26-27, 2020

CHI’s Third Annual Bispecific Case Studies & Clinical Relevance conference will bring together clinicians, regulators, and industry experts in the field to discuss and exchange ideas on promising bispecific candidates. We will showcase all crucial topics from understanding the biology behind different bispecific constructs to mitigating challenges in advancing novel platforms to the clinic. Leading players will be sharing their experience and lessons learned in clinical trials. An extension of bispecific applications in other diseases besides oncology will also be discussed.

Preliminary Agenda

Advances in Oncologic Bispecific Biologics: Top Ten Challenges and Opportunities

Rakesh Dixit, PhD, DABT, President and CEO, BIONAVIGEN, LLC

Lesson Learned in Developing Bispecific Antibodies

Ulrich Brinkmann, PhD, Expert Scientist, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, FRG

Modulating Cancer Immunity with Multi-Specific Antibodies

Nathan Trinklein, PhD, Chief Technology Officer, Teneobio

PANEL DISCUSSION: CAR T Versus Bispecific Antibody – Who Wins?

Moderator: G. Jonah Rainey, PhD, Vice President, Antibody Therapeutics, Gritstone Oncology, Inc.

Using the Adimab Anti-CD3 Panel to Find the Balance between Safety and Efficacy

Paul Widboom, PhD, Associate Director, Antibody Discovery, Adimab LLC

Pharmacokinetics and Immunogenicity of Three Anti-HER2/CD3 T Cell-Dependent Bispecific (TDB) with Varying Affinities to Their Targets in Cynomolgus Monkeys

Meric Ovacik, PhD, Scientist, Preclinical and Translational Pharmacokinetics in Development Sciences, Genentech

Development of a mPBPK/PD Model to Characterize Target Cell Depletion and Cytokine Release for T Cell-Redirecting Bispecific Agents in Humans

Weirong Wang, PhD, Director, Clinical Translational Modeling, Clinical Pharmacology and Pharmacometrics (CPP), Quantitative Sciences, Janssen Research & Development, LLC

Measurement of Circulating Immune Complexes of a Bispecific Monoclonal Antibody

Robert Hendricks, PhD, Senior Research Associate, Development Sciences, Genentech

PANEL DISCUSSION: Predicting and Mitigating Immunogenicity for Bispecific Therapeutics

Moderator: Meric Ovacik, PhD, Scientist, Preclinical and Translational Pharmacokinetics, Development Sciences, Genentech

For more details on the conference, please contact:
Emily Le

Conference Producer

Cambridge Healthtech Institute

Phone: 781-247-1812
Email: ele@healthtech.com

For partnering and sponsorship information, please contact:

Companies A-K

Jason Gerardi

Senior Manager, Business Development